{"name":"AMNEAL PHARMS","slug":"amneal-pharms","ticker":"","exchange":"","domain":"amnealpharms.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-02","label":"ALYMSYS Phase 3 readout (Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"ALYMSYS Phase 3 readout (Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-31","label":"ALYMSYS Phase 3 readout (Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"ALYMSYS Phase 3 readout (Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-15","label":"ALYMSYS Phase 2 readout (Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-01-01","label":"ALYMSYS Phase 3 readout (Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-07-01","label":"ALYMSYS Phase 3 readout (Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-10","label":"ALYMSYS Phase 3 readout (Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-02-28","label":"ALYMSYS Phase 3 readout (Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-12-31","label":"ALYMSYS Phase 3 readout (Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma)","drug":"ALYMSYS","drugSlug":"bevacizumab-maly","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALYMSYS","genericName":"BEVACIZUMAB-MALY","slug":"bevacizumab-maly","indication":"Metastatic Colorectal Cancer - First/Second Line","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BONCRESA","genericName":"DENOSUMAB-MOBZ","slug":"denosumab-mobz","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ALYMSYS","genericName":"BEVACIZUMAB-MALY","slug":"bevacizumab-maly","phase":"marketed","mechanism":"","indications":["Metastatic Colorectal Cancer - First/Second Line","Metastatic Colorectal Cancer - Second Line Post Bevacizumab","Non-Squamous Non-Small Cell Lung Cancer - First Line","Recurrent Glioblastoma","Metastatic Renal Cell Carcinoma"],"catalyst":""},{"name":"BONCRESA","genericName":"DENOSUMAB-MOBZ","slug":"denosumab-mobz","phase":"marketed","mechanism":"Denosumab binds to RANKL, preventing it from activating RANK on osteoclasts, reducing bone resorption and increasing bone mass.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}